Therapeutic efficacy of buforin II and rifampin in a rat model of Acinetobacter baumannii sepsis

Critical Care Medicine

Volumn 37, Issue 4, 2009, Pages 1403-1407

  Cirioni, Oscar ^a   Silvestri, Carmela ^a   Ghiselli, Roberto ^a   Orlando, Fiorenza ^b   Riva, Alessandra ^a   Gabrielli, Eleonora ^a   Mocchegiani, Federico ^a   Cianforlini, Nancy ^a   Trombettoni, Maria Michela Cappelletti ^a   Saba, Vittorio ^a   Scalise, Giorgio ^a   Giacometti, Andrea ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

A. baumannii; Animal model; Antimicrobial peptides; Multiresistant organisms; Sepsis; Synergy

Indexed keywords

ANTIINFECTIVE AGENT; BUFORIN II; ENDOTOXIN; INTERLEUKIN 6; RIFAMPICIN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL MODEL; MALE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SEPSIS; SINGLE DRUG DOSE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; DISEASE MODELS, ANIMAL; MALE; PROTEINS; RATS; RATS, WISTAR; RIFAMPIN; SEPSIS;

EID: 67650480375     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e31819c3e22     Document Type: Article

References (26)

1. McGowan JE Jr: Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum. Am J Med 2006; 119:S29-S36
2. Diekema DJ, BootsMiller, BJ, Vaughn TE, et al: Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 2004; 38:78-85
3. Rossolini GM, Mantengoli E, Docquier JD, et al: Epidemiology of infections caused by multiresistant gram-negative: ESBLs, MBLs, panresistant strains. New Microbiol 2007; 30: 332-339
4. Vila J, Martì S, Sanchez-Céspedes J: Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Che-mother 2007; 59:1210-1215
5. Paterson DL: The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43:S43-S48
6. Jain R, Danziger LH: Multidrug-resistant Acinetobacter infections: An emerging challenge to clinicians. Ann Pharmacother 2004; 38:1449-1459
7. Motaoukkil S, Charra B, Hachimi A, et al: Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 2006; 53: 274-278
8. Rahal JJ: Novel antibiotic combination against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43: S95-S99
9. Safdar N, Handelsman J, Maki D: Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-527
10. Vergidis PI, Falagas ME: Multidrug-resistant Gram-negative bacterial infections: The emerging threat and potential novel treatment options. Curr Opin Investig Drugs 2008; 9:176-183
11. Cannon M: A family of wound healers. Nature 1987; 328:478
12. Boman HG: Antibacterial peptides: Basic facts and emerging concepts. J Intern Med 2003; 254:197-215
13. Hancock REW: Cationic peptides: Effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 2001; 1:156-164
14. Giacometti A, Cirioni O, Barchiesi F, et al: Antimicrobial activity of polycationic peptides. Peptides 1999; 20:1265-1273
15. Gough M, Hancock REW, Kelly NM: Antien-dotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64: 4922-4927
16. Hancock REW, Scott MG: The role of anti- microbial peptides in animal defenses. Proc Natl Acad Sci USA 2000; 97:8856-8861
17. Giacometti A, Cirioni O, Ghiselli R, et al: The bovine antimicrobial peptide BMAP-28 reduces lethality due to bacterial cell wall components in mouse models of staphylococcal sepsis. Crit Care Med 2004; 32:2485-2490
18. Park CB, Kim HS, Kim SC: A novel antimicrobial peptides from Bufo bufo gargarizans. Biochem Biophys Res Commun 1996; 218: 408-413
19. Park CB, Kim HS, Kim SC: Mechanisms of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Com-mun 1998; 244:253-257
20. Clinical and Laboratory Standards Institute (CLSI): Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard M7-A6. Villanova, PA, CLSI, 2003
21. Eliopoulos GM, Moellering RC Jr: Antimicrobial combinations. In: Antibiotics in Laboratory Medicine. Lorian V (Ed). Baltimore, MD, Williams and Wilkins, 1996, pp 330-393
22. Vaara M, Porro M: Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria. Antimicrob Agents Chemother 1996; 40: 1801-1805
23. Cirioni O, Giacometti A, Ghiselli R, et al: Citropin 1.1-treated central venous catheters improve the efficacy of hydrophobic antibiotics in the treatment of experimental staphylococcal catheter-related infection. Peptides 2006; 27:1210-1216
24. Yeaman MR, Yount NY: Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 2003; 55:27-55
25. McCafferty DG, Cudic P, Yu MK, et al: Synergy and duality in peptide antibiotic mechanisms. Curr Opin Chem Biol 1999; 3:672-680
26. Kobayashi S, Chikushi A, Tougu S, et al: Membrane translocation mechanism of the antimicrobial peptide buforin 2. Biochemistry 2004; 43:15610-15616